Latigo Biotherapeutics, Inc. (LTGO)

NASDAQ: LTGO · Real-Time Price · USD

20.06

+0.68 (3.51%)

At close: Aug 13, 2026, 4:00 PM EDT

20.01

-0.05 (-0.25%)

After-hours: Aug 13, 2026, 7:34 PM EDT

Latigo Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	13.84	10.86	6.67
Research & Development	98.48	99.53	56.78
Operating Expenses	112.32	110.39	63.45
Operating Income	-112.32	-110.39	-63.45
Interest & Investment Income	2.9	2.94	2.26
Other Non Operating Income (Expenses)	-1.76	-1.72	0
Pretax Income	-111.18	-109.17	-61.18
Net Income	-111.18	-109.17	-61.18
Net Income to Common	-111.18	-109.17	-61.18
Net Income Growth	-	-	-
Shares Outstanding (Basic)	6	5	4
Shares Outstanding (Diluted)	6	5	4
Shares Change	-	24.39%	-
EPS (Basic)	-19.74	-20.12	-14.02
EPS (Diluted)	-19.74	-20.12	-14.02
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-103.5	-97.69	-51.03
Free Cash Flow Per Share	-18.38	-18.00	-11.70
EBITDA	-112.09	-110.14	-63.21
D&A For EBITDA	0.23	0.25	0.24
EBIT	-112.32	-110.39	-63.45

SEC Filings: 10-K · 10-Q